A recent study using the Early-CDT® Lung Kit, which measures seven autoantibodies against p53, SOX2, CAGE, NY-ESO-1, GBU4-5, MAGE A4, and HuD, reported a sensitivity of 21% sensitivity for early stage (I–II) and an overall sensitivity of 33% with a specificity of 88% for lung cancer [23]. Here, TP53 is linked to lung carcinoma.